Historically, ERG has been a challenging drug target because it lacks well-defined binding pockets, the usual footholds small molecule drugs latch onto. However, the research team has now identified a previously unknown ligandable site within a specific region of the ERG protein known as the PNT domain. This discovery paved the way for the development of a small molecule probe, PBITE-1, designed to selectively bind and inhibit ERG’s oncogenic activity.

The researchers synthesized and screened over 1,600 compounds to find molecules capable of engaging the PNT domain. Through iterative optimization, they developed PBITE-1, which effectively disrupts ERG’s interaction with other proteins critical for cancer progression. In preclinical models—including prostate cancer cell lines and human and murine organ systems—PBITE-1 induced cancer cell death and prevented invasive behavior, demonstrating tangible anti-tumor effects.

This breakthrough is particularly significant because current prostate cancer treatments predominantly target androgen receptors, which activate ERG gene fusions that spur tumor development. While androgen receptor inhibitors can temporarily halt cancer growth, tumors often develop resistance, and patients endure severe side effects. PBITE-1 offers a new therapeutic strategy by directly targeting ERG, potentially circumventing resistance mechanisms associated with hormonal therapy.

Lead investigator Dr. Arul Chinnaiyan, who was instrumental in first identifying the TMPRSS2-ERG fusion, emphasized the importance of this discovery: “Our findings establish ERG as a druggable oncogenic driver, opening the door for personalized treatment strategies tailored to specific prostate cancer subtypes.” While PBITE-1 itself is not yet ready for clinical use, it represents a crucial proof of concept demonstrating that disrupting ERG function is feasible.

The study not only sheds light on the molecular intricacies of prostate cancer but also exemplifies how identifying previously hidden target sites on ‘undruggable’ proteins can propel therapeutic innovation. As drug development efforts continue, PBITE-1 and similar compounds may redefine treatment paradigms, offering hope for improved outcomes in one of men’s most deadly cancers.

Subject of Research: Animals
Article Title: A Ligandable PNT-Domain Establishes ERG as a Directly Targetable Oncogenic Driver in Prostate Cancer
News Publication Date: 7-Jul-2026
Web References: https://doi.org/10.1073/pnas.2537437123
Image Credits: Jessica Johnson
Keywords: Prostate cancer, ERG protein, TMPRSS2-ERG fusion, small molecule probe, PBITE-1, PNT domain, targeted therapy

Prostate cancer remains one of the most frequently diagnosed cancers among men worldwide, with approximately 15,000 new cases annually in the Netherlands alone. Standard treatment modalities—including surgery, radiation therapy, chemotherapy, and androgen deprivation therapy (ADT)—have significantly improved outcomes but often come with burdensome side effects and quality-of-life implications. PSMA therapy, which employs a radioactively labelled molecule ([177Lu]-PSMA-617) targeting the prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells, offers a unique internal radiotherapy that delivers cytotoxic radiation directly to cancerous sites while sparing healthy tissue.

The latest study focused on patients with oligometastatic hormone-sensitive prostate cancer, defined by the presence of up to five metastatic lesions. This patient population represents a critical window for intervention, where delay or modification of systemic therapies can drastically influence long-term disease trajectory and patient well-being. Conducted as a randomized, open-label phase 2 trial, the research enrolled 58 men who had undergone standard localized treatments, including surgery or targeted radiotherapy, but had not yet commenced conventional hormone therapies.

Participants were split evenly into two arms: one group received immediate PSMA-targeted radioligand therapy post-local treatment, while the control group was observed until disease progression and then treated with PSMA therapy. The experimental protocol consisted of four treatment cycles of [177Lu]-PSMA-617, meticulously dosed to optimize therapeutic effect while minimizing toxicity. All subjects were monitored for at least two years, allowing robust longitudinal assessment of treatment impact.

A striking divergence in disease progression emerged between the two groups. In the cohort receiving upfront PSMA therapy, only 52% showed disease progression by 27 months, compared to an alarming 97% in the control group. Moreover, initiation of subsequent hormone therapy—a standard but often debilitating intervention—was deferred by an average of twenty months among those treated early with PSMA radioligand therapy. This delay not only defers associated side effects, such as hot flashes, muscle weakness, and profound fatigue frequently likened to menopausal symptoms, but also preserves patients’ quality of life during a critical phase of their illness.

Notably, the therapy was well-tolerated, with minimal adverse events reported, reinforcing its safety profile. According to Dr. James Nagarajah, Nuclear Medicine Physician and principal investigator, these findings address a significant unmet clinical need. Patients increasingly seek alternatives to hormone therapy due to its impact on physical and psychological health. By offering a targeted radiation approach that effectively controls disease progression, PSMA therapy provides a compelling adjunct or perhaps future alternative to systemic hormone suppression.

Another remarkable observation was the potential of PSMA therapy to convert patients back to eligibility for localized treatments. Bastiaan Privé, the study’s first author, emphasized that in some cases, the therapy substantially reduced tumor burden, enabling patients to receive additional rounds of targeted radiation. This cyclical therapeutic strategy could further extend periods free from systemic hormone therapy, maximizing disease control while minimizing cumulative toxicity.

These results, recently published in the prestigious journal The Lancet Oncology, not only advance the scientific understanding of prostate cancer biology and therapeutic response but also open new avenues for clinical decision-making. As researchers deepen exploration into the optimal timing, dosing, and combination strategies for PSMA radioligand therapy, patient-centered outcomes remain at the forefront, balancing efficacy with quality of life considerations.

The implications of this work extend beyond immediate clinical application. The concept of targeting cancer with radiolabeled ligands against specific cell surface markers embodies a paradigm shift towards precision oncology—an era where treatments are increasingly personalized based on tumor biology rather than relying solely on traditional systemic therapies. This trial exemplifies how integrating molecular imaging and targeted therapeutics can revolutionize prostate cancer management, potentially applicable to other malignancies expressing unique molecular targets.

While the study’s sample size limits broad generalization, the compelling efficacy signals warrant larger-scale trials to confirm these findings and elucidate long-term survival benefits. The multi-institutional collaboration, including participation from prominent centers such as Amsterdam UMC and UMCG, underscores the scientific rigor and translational potential of this innovative treatment strategy.

In summation, PSMA-targeted radioligand therapy emerges as a transformative approach for men with limited metastatic prostate cancer, effectively delaying the onset of hormone therapy and preserving quality of life. This adds a powerful new weapon to the oncologist’s arsenal, offering hope to patients seeking less invasive yet highly efficacious treatment options. Continued research is poised to refine and expand this therapeutic modality, moving toward an era where prostate cancer can be managed with precision, minimizing toxicity, and maximizing survival.

As the scientific community digests these findings, the message is clear: targeting prostate cancer cells with radiolabeled molecules not only extends survival but also enhances patients’ lived experience by alleviating the hardships of conventional hormone treatments. This harmonizes with modern oncology’s overarching goals—achieving optimal treatment outcomes while safeguarding quality of life. The advent of PSMA radioligand therapy marks a turning point that could soon transform clinical practice guidelines and patient care worldwide.

Subject of Research: People
Article Title: [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
News Publication Date: 30-Mar-2026
Image Credits: Source: Radboudumc
Keywords: Prostate cancer, Medical treatments, Clinical trials, Drug studies

At the heart of this discovery lies the androgen receptor (AR), a well-established protein driver fueling the progression of prostate cancer. PDIA1 and PDIA5 serve as indispensable molecular chaperones, ensuring the stability and functional integrity of the AR within cancerous cells. Through complex biochemical interactions, these enzymes safeguard the AR from degradation, thereby enabling continuous oncogenic signaling that supports tumor growth. When the activities of PDIA1 and PDIA5 are inhibited, this protective effect disintegrates, triggering the destabilization and proteasomal breakdown of AR, ultimately inducing apoptosis in cancer cells and causing measurable tumor regression.

Critically, the researchers demonstrated that pharmacological inhibition of PDIA1 and PDIA5 not only undermines AR stability but also amplifies the therapeutic efficacy of enzalutamide—an androgen receptor signaling inhibitor widely used in prostate cancer treatment. This combination treatment synergistically impaired cancer cell viability far more effectively than enzalutamide alone, as confirmed in both laboratory cultured cells and multiple animal models. These results delineate a promising avenue to counteract the notorious resistance that often develops against conventional hormone therapies in advanced prostate cancer cases.

Professor Luke Selth, an eminent figure in prostate cancer research and senior author on the study, highlights the significance of the discovery: “We have uncovered a previously uncharacterized mechanism that prostate cancer cells exploit to shield the androgen receptor, a pivotal oncogenic driver. Targeting PDIA1 and PDIA5 disrupts this defense, rendering tumors more susceptible to existing anti-androgen therapies such as enzalutamide.” This insight opens a new frontier in the quest for therapeutic regimens that can overcome the adaptive resistance often encountered during treatment.

Contributing to the robustness of this research, lead author Professor Jianling Xie noted that the dual blockade of PDIA1 and PDIA5 exhibited potent anti-cancer effects in patient-derived tumor samples and in vivo mouse models, both of which closely mimic human tumor biology. “Our data strongly support the translational potential of this combination therapy, warranting further rigorous clinical trials that could eventually improve patient outcomes,” Dr. Xie explained, now continuing her research at South China University of Technology.

Beyond their role as molecular bodyguards of the androgen receptor, PDIA1 and PDIA5 were found to exert additional oncogenic functions by regulating cellular stress responses and bioenergetic homeostasis. The study highlighted that inhibiting these enzymes results in mitochondrial dysfunction, impairing energy production within cancer cells and elevating reactive oxygen species (ROS). This oxidative stress exacerbates cellular damage, synergizing with AR destabilization to compound tumor cell lethality.

This multifaceted attack—simultaneously impairing AR signaling and cellular metabolism—positions PDIA1 and PDIA5 as uniquely attractive therapeutic targets. According to Dr. Xie, “By cutting off both the fuel supply and the engine driving prostate cancer, we effectively starve and immobilize the tumor’s capacity to survive and expand.” This dual mechanism is particularly notable in the context of developing treatments that can circumvent therapeutic resistance and target cancer on multiple biological fronts.

However, Professor Selth cautioned that current inhibitors targeting PDIA enzymes are still in the developmental phase. While promising, some existing compounds lack specificity and may damage healthy cells, thereby posing safety concerns. Future research efforts will focus on the rational design of more selective and less toxic PDIA inhibitors, optimizing their pharmacological profiles to enhance clinical applicability and minimize off-target effects.

The relevance of these findings is underscored by the epidemiological burden of prostate cancer, which ranks as the second most common cancer among men globally. Despite advances in hormone therapy and AR-directed drugs, resistance remains a formidable barrier to long-term disease control, especially in advanced and metastatic stages. The identification of PDIA1 and PDIA5 as central players in this resistance mechanism heralds a potential paradigm shift in therapeutic strategies aimed at durable cancer suppression.

The study was funded by a consortium of organizations committed to cancer research, including Cancer Council SA, Cancer Council NSW, the Flinders Foundation, the Movember Foundation, the Prostate Cancer Foundation of Australia, The Hospital Research Foundation, Cancer Australia, the Masonic Charities Trust, the Australian Research Council, and several international collaborators. This collaboration underscores the global priority placed on tackling prostate cancer through innovative scientific inquiry.

Full elucidation of the mechanisms by which PDIA1 and PDIA5 stabilize the androgen receptor and support cancer metabolism provides a valuable framework for the development of next-generation combination therapies. Such approaches may not only extend survival but also improve the quality of life for men afflicted with this disease. The prospect of therapies that more comprehensively disrupt cancer cell survival pathways offers renewed hope in the ongoing battle against prostate cancer.

Moving forward, the translation of this preclinical research into clinical success will depend on meticulous drug development, coupled with carefully designed clinical trials to establish efficacy and safety in humans. The path from bench to bedside may be challenging, but the evidence presented heralds a promising future for men confronting this diagnosis.

Subject of Research: Animals
Article Title: Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival
News Publication Date: 17-Oct-2025
Web References: DOI: 10.1073/pnas.2509222122
References: Jianling Xie et al., PNAS, 2025;122:e2509222122
Image Credits: Professor Luke Selth, Flinders Health and Medical Research Institute (FHMRI) and College of Medicine and Public Health, Flinders University
Keywords: prostate cancer, androgen receptor, PDIA1, PDIA5, enzyme inhibition, enzalutamide, therapeutic resistance, mitochondrial dysfunction, oxidative stress, combination therapy, molecular chaperones, cancer metabolism

Emerging from the study of intracellular trafficking regulators, RAB26 has attracted attention due to its role in cell signaling and vesicular transport. Through meticulous single-cell RNA sequencing analysis (notably from dataset GSE141445), researchers have delineated the expression landscape of RAB26 across heterogeneous prostate cancer cell populations. The data reveal a pronounced expression of RAB26 in luminal as well as basal and intermediate prostate cancer cells, suggesting its involvement across diverse cellular compartments within the tumor microenvironment.

Intriguingly, elevated RAB26 expression correlates robustly with pathological aggressiveness. Statistical analyses demonstrate that higher RAB26 levels are significantly associated with advanced tumor stage, elevated Gleason scores—a hallmark indicator of prostate cancer severity—and worse clinical outcomes measured by progression-free and disease-free survival metrics. This association underscores RAB26 not only as a biomarker of tumor burden but potentially as an active contributor to malignant progression.

Functional assays conducted in vitro lend substantial weight to this hypothesis. Experimental overexpression of RAB26 enhances prostate cancer cell proliferation, augments migratory and invasive capabilities, and confers resistance to apoptotic stimuli. Moreover, RAB26 expression fosters the maintenance of stem-like properties in prostate cancer stem cells (PCSCs), which are implicated in tumor initiation, metastasis, and therapeutic resistance. Enhanced sphere formation assays substantiate the role of RAB26 in sustaining these renewal-capable cellular subpopulations.

To elucidate the molecular underpinnings of RAB26’s oncogenic influence, researchers turned to transcriptome-wide profiling. The results spotlight the activation of the MAPK/ERK signaling cascade as a pivotal downstream effector of RAB26. This pathway is well-documented for governing cell proliferation, survival, and motility, and its aberrant activation is a common feature in diverse cancers. Importantly, the study connects RAB26 activity to the promotion of epithelial–mesenchymal transition (EMT), a phenotypic shift enabling epithelial cells to acquire mesenchymal traits, facilitating invasion and metastasis.

Central to the EMT process is the transcription factor TWIST1. The study unravels a novel interplay wherein RAB26 enhances the nuclear localization of TWIST1, thereby potentiating its transcriptional programs driving EMT. Remarkably, TWIST1 reciprocally upregulates RAB26 expression, establishing a self-reinforcing positive feedback loop. This synergistic crosstalk amplifies oncogenic signaling, perpetuating tumor progression and metastatic potential.

The functional significance of this MAPK/ERK-TWIST1-RAB26 axis was further validated in vivo using prostate cancer xenograft models. Silencing of RAB26 not only led to significant tumor growth suppression but also diminished stemness markers within the tumors and reduced lung metastases—a major cause of morbidity in advanced prostate cancer patients. These findings confirm RAB26 as a driver of both tumorigenesis and dissemination.

Beyond mechanistic insights, the translational potential of targeting RAB26 is profound. As a membrane-associated GTPase involved in vesicular trafficking, RAB26 presents unique opportunities for pharmacological intervention. Targeted therapies designed to disrupt the MAPK/ERK-TWIST1-RAB26 axis could impede tumor progression and overcome resistance, offering hope for clinical management of aggressive prostate cancer subtypes.

Importantly, clinical data support the prognostic utility of RAB26 measurement. Immunohistochemical analyses showcase elevated RAB26 protein levels in tumor tissues compared to benign counterparts, correlating with advanced Gleason grades and lymph node metastases. These attributes position RAB26 as an attractive biomarker for risk stratification and patient monitoring.

The investigative team, based at Chongqing Medical University, underscores the broader implications of their findings. By integrating high-resolution single-cell genomics with functional assays and in vivo validation, they provide a comprehensive portrait of RAB26’s oncogenic role. This multidisciplinary approach paves the way for future studies exploring RAB26-targeted drugs and combinatorial strategies with existing therapeutics.

In summary, the discovery of RAB26’s engagement in prostate cancer progression via the MAPK/ERK-TWIST1 signaling axis represents a significant leap forward. As prostate cancer continues to challenge clinicians, this research delineates new molecular targets and refines our understanding of tumor biology. Ultimately, such advances could catalyze the development of innovative therapies that improve survival and quality of life for patients afflicted with this formidable disease.

Subject of Research: Molecular mechanisms driving prostate cancer progression, specifically focusing on RAB26 and its role in tumor biology.

Article Title: RAB26 promotes prostate cancer progression via the MAPK/ERK-TWIST1 signaling axis

References:
Wang, H., Liang, S., Du, X., Zhao, G., Bai, Y., Li, J., Xu, H., Peng, S., Yuan, Y., Tang, W. (2025). RAB26 promotes prostate cancer progression via the MAPK/ERK-TWIST1 signaling axis. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101689

Image Credits: Hexi Wang, Simin Liang, Xiaoyi Du, Guozhi Zhao, Yuanyuan Bai, Junwu Li, Haoyu Xu, Senlin Peng, Ye Yuan, Wei Tang

Keywords: Prostate cancer, RAB26, MAPK/ERK pathway, TWIST1, epithelial-mesenchymal transition, cancer stem cells, tumor progression, metastasis, biomarker, single-cell RNA sequencing